Skip to content
Journal articleRTP-00000999Open AccessDOI 10.1016/s0140-6736(18)32409-7

Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial

The Lancet · 2019 · Elsevier BV

4 views · 0 downloads

Citations by source

  • openalex3390

Counts differ by provider and are shown separately, never combined.